Resmetirom

Resmetirom

Clinical data
Other names	MGL-3196
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile
CAS Number	920509-32-6
PubChem CID	15981237
DrugBank	DB12914
UNII	RE0V0T1ES0
KEGG	D11602
ChEMBL	ChEMBL3261331
Chemical and physical data
Formula	C17H12Cl2N6O4
Molar mass	435.22 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl
InChI InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28) Key:FDBYIYFVSAHJLY-UHFFFAOYSA-N

Resmetirom is an experimental drug for the treatment of non-alcoholic steatohepatitis (NASH). It is a selective agonist of thyroid hormone receptor-β which increases hepatic fat metabolism and reduces lipotoxicity.

As of 2023, it is in Phase III clinical trials.